Hereditary cancer genetic testing identifies mutations in genes that significantly elevate lifetime cancer risk. For gynecologic health, the most clinically significant mutations are in the BRCA1 and BRCA2 genes (breast and ovarian cancer syndrome) and the mismatch repair genes MLH1, MSH2, MSH6, PMS2, and EPCAM (Lynch syndrome, associated with endometrial, ovarian, and colorectal cancer). Additional genes — PALB2, CHEK2, ATM, RAD51C, RAD51D, and others — confer intermediate to elevated cancer risks and are included in multi-gene cancer panels now widely available.
The clinical value of identifying a hereditary cancer mutation is extraordinary: it provides a specific lifetime cancer risk estimate that guides surveillance intensity and timing, creates the basis for considering risk-reducing medications and surgery, and identifies family members who should be offered cascade testing. For women who test positive for BRCA1 or BRCA2 mutations and undergo risk-reducing salpingo-oophorectomy at the appropriate time, ovarian cancer mortality is reduced by more than 80 percent. This is among the most dramatic risk reduction achievable in any area of cancer prevention.
BRCA1 Mutation — High-Risk Breast and Ovarian Cancer
Lifetime breast cancer risk: 55 to 72 percent (vs 12 percent population risk). Lifetime ovarian cancer risk: 40 to 46 percent (vs 1.4 percent population risk). Management for BRCA1 carriers includes: annual breast MRI beginning at age 25 and annual mammography from age 30; risk-reducing salpingo-oophorectomy (removal of fallopian tubes and ovaries) between ages 35 and 40 after childbearing is complete, which reduces ovarian cancer risk by more than 80 percent and reduces breast cancer risk when performed before natural menopause; consideration of risk-reducing mastectomy (bilateral prophylactic mastectomy) which virtually eliminates breast cancer risk; and chemoprevention with medications including tamoxifen and aromatase inhibitors that reduce breast cancer risk modestly without surgery. BRCA1-associated ovarian cancer tends to occur at a younger age than BRCA2-associated disease, which is why risk-reducing oophorectomy is recommended in the mid-30s for BRCA1 carriers.
BRCA2 Mutation — High-Risk Breast and Ovarian Cancer
Lifetime breast cancer risk: 45 to 69 percent. Lifetime ovarian cancer risk: 11 to 27 percent. Management is similar to BRCA1 but risk-reducing oophorectomy timing is extended to age 40 to 45 for BRCA2 carriers because ovarian cancer risk is lower and onset is later. Male BRCA2 carriers have elevated risks of breast cancer, prostate cancer, and pancreatic cancer — making the paternal family history of BRCA2 equally important to the maternal history.
Lynch Syndrome — Elevated Endometrial and Ovarian Cancer Risk
Lifetime endometrial cancer risk: 15 to 60 percent depending on the mutated gene. Lifetime ovarian cancer risk: 5 to 15 percent. Lifetime colorectal cancer risk: 25 to 80 percent depending on the gene. Management for Lynch syndrome carriers includes: annual endometrial biopsy and/or transvaginal ultrasound surveillance beginning at age 30 to 35; colonoscopy every 1 to 2 years beginning at age 20 to 25; risk-reducing hysterectomy with bilateral salpingo-oophorectomy considered after childbearing is complete, which eliminates the risk of endometrial and ovarian cancer from Lynch syndrome; and aspirin as chemoprevention (evidence for colorectal cancer risk reduction in Lynch syndrome). Lynch syndrome is more common than BRCA mutations — affecting approximately 1 in 280 individuals — and significantly underdiagnosed.
Intermediate-Risk Genes — PALB2, CHEK2, ATM, and Others
Multi-gene cancer panels now identify mutations in intermediate-penetrance genes including PALB2, CHEK2, ATM, RAD51C, and RAD51D that confer elevated cancer risks below the level of BRCA1/2. PALB2 mutations in particular carry a lifetime breast cancer risk approaching that of BRCA2. Management recommendations for intermediate-risk genes are evolving as more data accumulates, and are individualized based on the specific gene and the family history context. Genetic counselors interpret these results in the context of the full clinical picture.
Family History Identification
The pathway begins with a thorough family history review at the well-woman visit. Dr. Andrei identifies patterns consistent with hereditary cancer syndromes, assesses eligibility for genetic testing based on current guidelines, and discusses what genetic testing might reveal and why it would be clinically actionable for the specific patient.
Genetic Counseling Referral
Women for whom genetic testing is indicated are referred to genetic counselors in our affiliated network. The genetic counseling visit provides a comprehensive pre-test consultation: detailed risk assessment, discussion of all available testing options, explanation of what positive and negative results mean, psychological preparation for possible results, and informed consent for testing. Testing typically uses a saliva or blood sample and results are available in 2 to 4 weeks.
Result-Based Management Coordination
After genetic testing results are returned and explained by the genetic counselor, Dr. Andrei coordinates the specific gynecologic management recommendations that follow: surveillance protocol, timing of risk-reducing surgery discussions, coordination with breast surgery, medical oncology, or other specialists as needed, and cascade testing recommendations for family members who may share the mutation.
A positive BRCA1 test result in a woman who acts on it — with enhanced surveillance, discussion of risk-reducing oophorectomy at the appropriate time, and family notification that enables cascade testing in relatives who may also carry the mutation — has the potential to prevent multiple cancers across a family over decades. The knowledge is powerful precisely because the interventions it enables are so effective.
If your family history suggests you may be a candidate for hereditary cancer genetic testing, the conversation starts at your well-woman visit at Lapeer Women’s Health — at either our Lapeer or Rochester Hills offices, without a referral required.
Our team at Lapeer Women’s Health identifies genetic testing candidates and coordinates genetic counseling referrals. No referral required.
Schedule a Gynecologic VisitEducational purposes only. Not medical advice. Content reviewed by Dr. Ramona D. Andrei, MD PhD FACOG.
Gynecologic care for women of every age
Lapeer Women’s Health — Rochester Hills
2710 S Rochester Rd, Suite 2
Rochester Hills, MI 48307
Serving patients in Lapeer, Rochester Hills, and surrounding communities throughout Southeast Michigan.